RT Journal Article SR Electronic T1 Acute Migraine: Which Triptan? JF Practical Neurology JO Pract Neurol FD BMJ Publishing Group Ltd SP 6 OP 19 DO 10.1111/j.1474-7766.2004.03-205.x VO 4 IS 1 A1 Jonathan P. Gladstone A1 David W. Dodick YR 2004 UL http://pn.bmj.com/content/4/1/6.abstract AB INTRODUCTION Primary headache disorders are the most frequent reason for referral to neurologists worldwide, and most of these patients have migraine (Menken 1996; Sempere et al. 2002; Rajput et al. 1988). Migraine is a common and frequently incapacitating headache disorder characterized by episodic attacks of moderate-to-severe headache, along with various combinations of neurological, gastrointestinal and autonomic symptoms (Goadsby et al. 2002). The one-year prevalence of migraine is 11% in the United States and Western Europe (6% for males and 15–18% for females) and one quarter of migraine patients experience one or more attacks per week (Goadsby et al. 2002; Hamelsky et al. 2001). A recent report by the World Health Organization ranks migraine as one of the most disabling chronic conditions and equates a day with severe migraine to the disability associated with a day with quadriplegia, psychosis or dementia (Menken et al. 2000).The aggregate impact of migraine